… Here we evaluated antibodies forming the basis of five mAb therapies in clinical … vivo efficacy
against infection by SARS-CoV-2 variants. Monotherapy with LY-CoV555, an antibody that …

… theoretical maximum monoclonal antibody efficacy, which assumes that endogenous
neutralising antibody responses provide the same protection as monoclonal antibody treatment. If …

… predictive of the efficacy of both monoclonal antibodies (p<0·… the dose administered and
efficacy in preventing hospitalisation (… antibody was expected to provide more than 30% efficacy …

… of these monoclonal antibodies and has limited efficacy in … of anti-SARS-CoV-2 monoclonal
antibodies with optimized … Fcγ receptors results in improved efficacy in both preventing and …

… It is generally well-tolerated and has induced an immune response against SARS-CoV-2
antigens in a Phase I study. IgA ASC (antibody secreting cells) were the most important …

… antibodies for SARS-CoV-2 infection, even in some with high antibody titers. However,
the occurrence of reinfection is rare for over 7 months of follow-up after the first antibody-positive …

… SARS-CoV-2 antibody products were defined as treatments involving exogenous antibodies
that act upon epitopes on SARS-CoV… to anti-SARS-CoV-2 antibody products were based …

… a patient with SARS-CoV-1. We hypothesized that a monoclonal antibody that neutralizes …
conserved epitope that would be functionally retained as SARS-CoV-2 evolves (Fig. S1 in the …

… In addition, the SARS-CoV RBD-based … antibodies which protect against SARS-CoV
infections (15). Thus, to identify SARS-CoV-2 mAbs, we generated two variants of the SARS-…

… Additionally, this work provides useful guidance in predicting vaccine efficacy against novel
SARS-CoV-2 variants as they are observed, informing the optimal deployment of current …